A. van’t Veen

722 citations

26 papers · 494 indexed · h-index 13

Impact in

Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria
Critical Care and Intensive Care Medicine top 10%
- Nosocomial Infections in ICU

Papers in

Applied Microbiology and Biotechnology 2
Molecular Medicine 4
- Antibiotic Resistance in Bacteria 4

Co-authors: Burkhard Lachmann Diederik Gommers Johan W. Mouton Serge J. C. Verbrugge A. G. M. Buiting Jan Kluytmans Dick Tibboel K. Hählen
Journals: Journal of Clinical Microbiology (3 papers)Intensive Care Medicine (3 papers)British Journal of Pharmacology (3 papers)Advances in experimental medicine and biology (2 papers)International Archives of Allergy and Immunology (1 paper)
Partner nations: Netherlands United States Belgium

In The Last Decade

A. van’t Veen

25 papers receiving 476 citations

Peers

Countries citing papers authored by A. van’t Veen

Since Specialization

Citations

This map shows the geographic impact of A. van’t Veen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. van’t Veen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. van’t Veen more than expected).

Fields of papers citing papers by A. van’t Veen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. van’t Veen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. van’t Veen. The network helps show where A. van’t Veen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside A. van’t Veen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. van’t Veen Line = papers co-authored together A. van’t Veen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Perspective on a Quality Management System for AI/ML-Based Clinical Decision Support in Hospital Care Frontiers in Digital Health ·Richard Bartels, Jeroen Dudink, Saskia Haitjema, Daniel L. Oberski, A. van’t Veen	2022	15
2	Detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories in the COMBACTE network: a COMBACTE LAB-Net survey International Journal of Antimicrobial Agents ·Tomislav Kostyanev, Tuba Vilken, Christine Lammens, Leen Timbermont, A. van’t Veen, Herman Goossens	2018	21
3	Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands Drugs & Therapy Perspectives ·Barbara Whelan, Eduardo Zayen, С./S. Николова/Nikolova, Dhavalkumar Gunvantlal Thakar, Adriana Avellaneda Bayona, Павел Сергеевич Биденко, Andres Veske, A. van’t Veen, Gerard Notario, Randy John Seeley	2016	8
4	O.2.4 Resurgence of mumps in The Netherlands (2007/2008): Vaccination failures and diagnostic failures go hand in hand Journal of Clinical Virology ·Rob van Binnendijk, Robert Kohl, E. Alstat, A. van’t Veen, Stephanie Carnell, Susan Hahné, Marion Koopmans, Hein J. Boot	2008	0
5	Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. PubMed ·Martijn J. ter Borg, Bettina E. Hansen, Eva Herrmann, Stefan Zeuzem, Yılmaz Çakaloğlu, Selim Karayalçın, Robert Flisiak, A. van’t Veen, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Bart L. Haagmans, (unknown)	2007	8
6	Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B Antiviral Therapy ·Martijn J. ter Borg, Bettina E. Hansen, Eva Herrmann, Stefan Zeuzem, Yılmaz Çakaloğlu, Selim Karayalçın, Robert Flisiak, A. van’t Veen, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Bart L. Haagmans, (unknown)	2007	8
7	Pseudo-Outbreak of Hepatitis B Virus Infection Associated With Contamination of a Semiautomatic Cap Remover Infection Control and Hospital Epidemiology ·B. M. W. Diederen, Carlo Verhulst, A. van’t Veen, P. H. J. van Keulen, Jan Kluytmans	2006	3
8	Outbreak of Infection with a Multiresistant Klebsiella pneumoniae Strain Associated with Contaminated Roll Boards in Operating Rooms Journal of Clinical Microbiology ·A. van’t Veen, Anneke van der Zee, M. Endler, B Speelberg, Jan Kluytmans, A. G. M. Buiting	2005	28
9	Schönlein-Henoch Purpura with Severe Duodenal Involvement Treated with Corticosteroids Endoscopy ·Jan A. M. van Laar, Maarten A.C. Meijssen, A. van’t Veen, Dena Pizzutti, M. van Blankenstein	1998	1
10	Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS) Intensive Care Medicine ·Diederik Gommers, E. P. Eijking, K. L. So, A. van’t Veen, Burkhard Lachmann	1998	20
11	Lung overinflation without positive end-expiratory pressure promotes bacteremia after experimental Klebsiella pneumoniae inoculation Intensive Care Medicine ·Serge J. C. Verbrugge, 伸治栗原, A. van’t Veen, Diederik Gommers, Burkhard Lachmann, Johan W. Mouton	1998	83
12	Exogenous Surfactant and Nitric Oxide Have a Synergistic Effect in Improving Gas Exchange in Experimental Ards Advances in experimental medicine and biology ·Lance Richard, Diederik Gommers, A. van’t Veen, W. Erdmann, Burkhard Lachmann	1997	8
13	Improved oxygenation by nitric oxide is enhanced by prior lung reaeration with surfactant, rather than positive end-expiratory pressure, in lung-lavaged rabbits Critical Care Medicine ·Diederik Gommers, Aleš Pipan, A. van’t Veen, Burkhard Lachmann	1997	16
14	Pretreatment with Spleen Peptides Can Enhance Survival in Influenza A Infected Mice Complementary Medicine Research ·A. van’t Veen, 次嘉高山, Johan W. Mouton, Peny Husna Handayani, Burkhard Lachmann	1996	2
15	Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae British Journal of Pharmacology ·A. van’t Veen, Johan W. Mouton, Diederik Gommers, Burkhard Lachmann	1996	48
16	Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity British Journal of Pharmacology ·A. van’t Veen, Diederik Gommers, Johan W. Mouton, Jan Kluytmans, Kasey Cordell, Burkhard Lachmann	1996	33
17	The prognosis of oncologic patients in the pediatric intensive care unit Intensive Care Medicine ·A. van’t Veen, Lihong Yin, Vyatcheslav L. L`vov, Dick Tibboel, K. Hählen, E. van der Voort	1996	52
18	Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin Antimicrobial Agents and Chemotherapy ·A. van’t Veen, Johan W. Mouton, Diederik Gommers, J. Kluytmans, Albert Marinho Ribas Semeler, Burkhard Lachmann	1995	36
19	Surfactant Replacement Therapy in Animal Models of Respiratory Failure Due to Viral Infection Advances in experimental medicine and biology ·A. van’t Veen, K. L. So, Burkhard Lachmann	1994	4
20	Protection against influenza a virus infection in mice by oral immunization with a polyvalent bacterial lysate International Journal of Immunopharmacology ·Rubén Sánchez Trigos, Jacobs-van der Bruggen Mam, K. L. So, Renato Aguirre, M Sprenger, Johan W. Mouton, A. van’t Veen, Burkhard Lachmann	1991	10

About A. van’t Veen

A. van’t Veen is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine, Health Informatics, Endocrine and Autonomic Systems and Clinical Biochemistry, having authored 26 papers that have together received 494 indexed citations. Recurring topics across this work include Neonatal Respiratory Health Research (7 papers), Respiratory Support and Mechanisms (7 papers), Pneumonia and Respiratory Infections (5 papers), Inhalation and Respiratory Drug Delivery (4 papers), Antibiotic Resistance in Bacteria (4 papers), Neuroscience of respiration and sleep (4 papers), Respiratory viral infections research (3 papers) and Bacterial Identification and Susceptibility Testing (3 papers). The work is most often cited by research in Molecular Medicine (68 citations), Critical Care and Intensive Care Medicine (61 citations), Applied Microbiology and Biotechnology (22 citations), Health Informatics (12 citations) and Pulmonary and Respiratory Medicine (278 citations). A. van’t Veen has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Burkhard Lachmann, Diederik Gommers, Johan W. Mouton, Serge J. C. Verbrugge, A. G. M. Buiting, Jan Kluytmans, Dick Tibboel, K. Hählen, E. van der Voort and K. L. So. Their work appears in journals such as Journal of Clinical Microbiology, Intensive Care Medicine, British Journal of Pharmacology, Advances in experimental medicine and biology and International Archives of Allergy and Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact